ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2014
Therapy for Parkinson's disease: what is in the pipeline?
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Stem Cell Therapies in Movement Disorders: Lessons from Clinical Trials.Biomedicines · 2023Review
- A metabolic biomarker predicts Parkinson's disease at the early stages in patients and animal models.The Journal of clinical investigation · 2022Article
- Contribution of syndecans to cellular uptake and fibrillation of α-synuclein and tau.Scientific reports · 2019Article
- Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase.Molecular diversity · 2019Article
- Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neurons.Neural regeneration research · 2017Review
- Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Outlining a Population "at Risk" of Parkinson's Disease: Evidence from a Case-Control Study.Parkinson's disease · 2016Article
- Editorial: Neurotherapeutics of movement disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in the treatment of Parkinson's disease there are still many unmet needs, including neuroprotection, treatment of motor complications, treatment of dyskinesia, treatment of psychosis, and treatment of nondopaminergic symptoms. In this review, I highlight the obstacles to develop a neuroprotective drug and some of the treatment strategies recently approved or still in clinical trials designed to meet these unmet needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.